Salspera’s immunotherapy, Saltikva®, will provide new hope to patients and oncologists in need of new, effective therapeutic options without toxicity or side effects. Proven safe in a human clinical study and through years of published efficacy studies in animals, Saltikva® is a genetically modified microbial agent, finding its way as a guided missile into solid tumors and activating the body’s own powerful immune response via NK cells.
Saltikva®, Salspera’s genetically engineered microbial agent expressing Interleukin-2, is nontoxic and targets solid tumors. It elicits the body’s immune response via NK cells without any known side effects.
Saltikva® has been shown in animal studies to enhance the effect of chemotherapy. In the presence of Saltikva®, scientists were able to reduce the dose of a commonly used chemotherapy by 75% while maintaining the same chemotherapy activity. Saltikva® provides hope for patients suffering from chemotherapy toxicity and adverse effects by helping to reduce the needed dosage.
A human clinical study and extensive animal clinical trials have shown that Saltikva® may be administered orally, providing hope for a more patient-friendly therapy and a simplified, streamlined in-clinic process.
FACT: Saltikva® has been shown in animal studies to reduce the need for large chemotherapy doses.